People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ansa Biotechnologies, Inc. | — | Biotechnology | Series C | $124.2M | $415.2M | 2022 |
| 1859, Inc. | — | Biotechnology | Series B | $52.2M | $877.6M | 2021 |
Lily Li at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Lily Li on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PAUL CONLEY | 1 | 17 |
| Jason T. Gammack | 1 | 2 |
| John Drewry | 1 | 2 |
| Chenny T. Zhang | 1 | 1 |
| Matthew T. McManus | 1 | 1 |
| Sebastian T. Palluk | 1 | 1 |
| Daniel Lin-Arlow | 1 | 1 |
| Sebastian Palluk | 1 | 1 |
| Sebastian Hillel Palluk | 1 | 1 |
| Daniel Hillel Lin-Arlow | 1 | 1 |
| Devon Cayer | 1 | 1 |
| Andrew MacConnell | 1 | 1 |
| Dan Faro | 1 | 1 |
| Yanniv T. Dorone | 1 | 1 |
| Daniel T. Lin-Arlow | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.